I-Penam 250 mg/vial contains Meropenem, a broad-spectrum carbapenem antibiotic intended for parenteral administration. It is used in adults and children to treat a wide range of serious bacterial infections caused by organisms sensitive to meropenem. Due to its strong bactericidal activity and stability against most beta-lactamases, meropenem is commonly reserved for moderate to severe infections, including those caused by resistant pathogens.

রেজিস্টার্ড চিকিৎসকের পরামর্শ অনুযায়ী ঔষধ সেবন করুন

Therapeutic Class

Other Beta-lactam Antibiotics (Carbapenem)

Pharmacology

Meropenem exerts its bactericidal effect by inhibiting bacterial cell wall synthesis. It penetrates bacterial cell walls efficiently and binds with high affinity to Penicillin Binding Proteins (PBPs), leading to rapid bacterial cell death. Meropenem is highly stable against serine beta-lactamases and demonstrates potent activity against a wide spectrum of Gram-positive, Gram-negative, aerobic, and anaerobic bacteria.

Indications

I-Penam 250 mg/vial is indicated for the treatment of the following infections in adults and children caused by susceptible organisms:

• Pneumonia and nosocomial pneumonia

• Urinary tract infections

• Intra-abdominal infections

• Gynaecological infections, including endometritis and pelvic inflammatory disease

• Skin and skin structure infections

• Meningitis

• Septicaemia

• Pulmonary infections in cystic fibrosis

• Empiric treatment of presumed infections in patients with febrile neutropenia

Dosage and Administration

The dosage and duration depend on the type and severity of infection and patient condition.

Adults:

• Usual dose: 500 mg to 1 g IV every 8 hours

• Severe infections (nosocomial pneumonia, septicaemia, neutropenia): 1 g IV every 8 hours

• Meningitis: 2 g IV every 8 hours

• Cystic fibrosis: up to 2 g IV every 8 hours

Children (3 months–12 years):

• 10–40 mg/kg IV every 8 hours depending on infection severity

• Meningitis: 40 mg/kg IV every 8 hours

• Febrile neutropenia: 20 mg/kg IV every 8 hours

• Children over 50 kg: Adult dosage

Meropenem should be administered by intravenous infusion over 15–30 minutes or by intravenous bolus over 3–5 minutes.

রেজিস্টার্ড চিকিৎসকের পরামর্শ অনুযায়ী ঔষধ সেবন করুন

Drug Interactions

• Probenecid may increase plasma levels of meropenem by reducing renal excretion.

• Meropenem may reduce serum valproic acid levels, potentially leading to sub-therapeutic concentrations.

Contraindications

Contraindicated in patients with known hypersensitivity to meropenem or other carbapenem antibiotics.

Side Effects

Meropenem is generally well tolerated. Possible adverse effects include injection-site reactions, thrombophlebitis, rash, pruritus, nausea, vomiting, diarrhea, abdominal pain, and headache.

Use in Special Populations

• Renal impairment: Dose adjustment required when creatinine clearance is <51 ml/min

• Hepatic impairment: No dose adjustment necessary

• Elderly: Dose adjustment only if renal function is impaired

• Children: Safety not established in infants below 3 months

Storage Conditions

Store the vial in a cool, dry place below 30°C, protected from light and moisture. Keep out of reach of children.